Payment overview · 2025
General Payments
$550.47
28 reported records · 10 companies
Healthcare provider profile · identity verified
Armando Antonio Doval, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DAVENPORT, FL · NPI 1982873477
Verified facts
What the public records show
CMS Open Payments records show Armando Antonio Doval, M.D. received $550.47 in general payments during 2025 across 28 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 240 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $154.28 | 28.0% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $130.88 | 23.8% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $101.56 | 18.4% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $59.14 | 10.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.84 | 3.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.85 | 3.4% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $18.64 | 3.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.01 | 3.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.36 | 2.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.91 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $550.47 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $100.82 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $81.99 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $81.99 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $79.83 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $60.11 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $59.14 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $53.46 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $51.05 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| ROTARIX Normalized: rotarix |
Biological | GlaxoSmithKline, LLC. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 100 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 112 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 240 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
84 | 19 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
112 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
78 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
240 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 473 | 144 |
| Levothyroxine Sodium | Levothyroxine Sodium | 346 | 99 |
| Losartan Potassium | Losartan Potassium | 325 | 95 |
| Omeprazole | Omeprazole | 262 | 71 |
| Gabapentin | Gabapentin | 260 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 259 | 74 |
| Ozempic | Semaglutide | 240 | 47 |
| Metformin Hcl | Metformin Hcl | 215 | 62 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 212 | 86 |
| Lisinopril | Lisinopril | 204 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 172 | 51 |
| Simvastatin | Simvastatin | 167 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 166 | 53 |
| Alprazolam | Alprazolam | 146 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 145 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 44 |
| Montelukast Sodium | Montelukast Sodium | 134 | 45 |
| Tramadol Hcl | Tramadol Hcl | 116 | 30 |
| Mounjaro | Tirzepatide | 112 | 21 |
| Glimepiride | Glimepiride | 110 | 35 |
| Clonazepam | Clonazepam | 105 | 32 |
| Prednisone | Prednisone | 102 | 61 |
| Eliquis | Apixaban | 100 | 27 |
| Carvedilol | Carvedilol | 99 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 99 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 95 | 53 |
| Allopurinol | Allopurinol | 93 | 23 |
| Furosemide | Furosemide | 93 | 38 |
| Meloxicam | Meloxicam | 93 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | 27 |
| Synthroid | Levothyroxine Sodium | 84 | 19 |
| Ezetimibe | Ezetimibe | 81 | 27 |
| Trulicity | Dulaglutide | 78 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 16 |
| Azithromycin | Azithromycin | 76 | 69 |
| Trazodone Hcl | Trazodone Hcl | 75 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 74 | 12 |
| Atenolol | Atenolol | 69 | 19 |
| Ibuprofen | Ibuprofen | 69 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 62 | 50 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 47 |
| Glipizide | Glipizide | 61 | 15 |
| Temazepam | Temazepam | 60 | 12 |
| Metformin Hcl Er | Metformin Hcl | 59 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 23 |
| Sertraline Hcl | Sertraline Hcl | 58 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 57 | 34 |
| Repatha Sureclick | Evolocumab | 57 | suppressed |
| Topiramate | Topiramate | 57 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 13 |
| Baclofen | Baclofen | 53 | 21 |
| Famotidine | Famotidine | 52 | 15 |
| Ondansetron Odt | Ondansetron | 51 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 16 |
| Fenofibrate | Fenofibrate | 49 | 14 |
| Jardiance | Empagliflozin | 48 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 48 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 13 |
| Spironolactone | Spironolactone | 43 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 12 |
| Ketoconazole | Ketoconazole | 41 | 11 |
| Sucralfate | Sucralfate | 41 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | 14 |
| Finasteride | Finasteride | 37 | 12 |
| Amoxicillin | Amoxicillin | 36 | 26 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 11 |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 19 |
| Lorazepam | Lorazepam | 33 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 33 | 11 |
| Pregabalin | Pregabalin | 31 | 17 |
| Ciclopirox | Ciclopirox Olamine | 29 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 28 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Ssd | Silver Sulfadiazine | 27 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Metronidazole | Metronidazole | 26 | 21 |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | 13 |
| Levofloxacin | Levofloxacin | 25 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 13 |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 23 | 16 |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Cefadroxil | Cefadroxil | 20 | 15 |
| Diazepam | Diazepam | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | 11 |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 17 |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Ciclopirox | Ciclopirox | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Tobramycin | Tobramycin | 14 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $550.47 · 28 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BEXSERO, BREZTRI, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, ROTARIX, Rybelsus, UBRELVY, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error